Compare Arm Holdings plc (ARM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arm Holdings plc vs Vertex Pharmaceuticals Incorporated — how do they compare? Arm Holdings plc trades at $316.95 (market cap $345.41B), while Vertex Pharmaceuticals Incorporated trades at $489.74 (market cap $123.19B). The key difference: Arm Holdings plc is far larger — about 2.8× Vertex Pharmaceuticals Incorporated's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | VRTX | |
|---|---|---|
Market Cap | $345.41B | $123.19B |
Sector | Technology | Health |
52-Week High | $439.46 | $529.59 |
52-Week Low | $104.55 | $366.54 |
Enterprise Value | $342.26B | $117.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Vertex Pharmaceuticals (VRTX) trades at $485.39, down 2.24% today but maintains a bullish technical trend with strong support at $486. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, though margins dipped slightly. Recent news highlights a strategic $10B acquisition of Crinetics Pharmaceuticals, expanding its endocrinology portfolio with potential $5B peak sales. Analyst consensus remains strongly bullish with an 83.9% buy rating and $526.50 price target.
Outlook is positive driven by earnings growth and strategic acquisitions, but risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. The stock offers upside to consensus targets but faces volatility near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
